# COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects

> **NCT00654485** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 940 (estimated)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT00654485
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** 940 (ESTIMATED)
- **Last updated:** 2009-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00654485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00654485, "COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00654485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*